Correction to Lancet Neurol 2025; 24: 316–30

Abstract

Bateman RJ, Li Y, McDade EM et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol 2025; 24: 316–30—In the Declaration of interests section of this Article, statements have been corrected for Alireza Atri. A grant number has been corrected, and the appendix has been resupplied. These corrections have been made to the online version as of July 9, 2025.